Enliven Therapeutics Announces Favorable Phase 1 Trial Results for CML Treatment

Enliven Therapeutics, Inc. has reported updated positive data from its Phase 1 ENABLE clinical trial for ELVN-001, a treatment for chronic myeloid leukemia. The company also shared key outcomes from its End-of-Phase 1 meeting with the FDA. These developments suggest promising progress in the drug's clinical evaluation.